Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,732 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Non-small cell lung cancer with synchronous brain metastases: Identification of prognostic factors in a retrospective multicenter study (HOT 1701).
Ohhara Y, Kojima T, Honjo O, Yamada N, Sato T, Takahashi H, Takamura K, Takashina T, Sukoh N, Tanaka H, Kawai Y, Fujita Y, Yokoo K, Hommura F, Harada T, Honda R, Amano T, Dosaka-Akita H, Oizumi S, Kinoshita I. Ohhara Y, et al. Among authors: amano t. Neurooncol Adv. 2024 Oct 5;6(1):vdae168. doi: 10.1093/noajnl/vdae168. eCollection 2024 Jan-Dec. Neurooncol Adv. 2024. PMID: 39539600 Free PMC article.
A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002).
Ikezawa Y, Asahina H, Oizumi S, Watanabe M, Takamura K, Kawai Y, Yamada N, Harada T, Kinoshita I, Fujita Y, Miyauchi E, Ogi T, Amano T, Furuta M, Sakakibara-Konishi J, Nishihara H, Dosaka-Akita H, Isobe H, Nishimura M; Hokkaido Lung Cancer Clinical Study Group. Ikezawa Y, et al. Among authors: amano t. Cancer Chemother Pharmacol. 2017 Nov;80(5):955-963. doi: 10.1007/s00280-017-3432-4. Epub 2017 Sep 13. Cancer Chemother Pharmacol. 2017. PMID: 28905108 Free article. Clinical Trial.
A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101).
Takashina T, Asahina H, Oizumi S, Yamada N, Harada M, Takamura K, Yokouchi H, Harada T, Honjo O, Ogi T, Morikawa N, Kinoshita I, Honda R, Nakano K, Kanazawa K, Amano T, Dosaka-Akita H, Isobe H, Nishimura M; Hokkaido Lung Cancer Clinical Study Group. Takashina T, et al. Among authors: amano t. Int J Clin Oncol. 2018 Dec;23(6):1060-1069. doi: 10.1007/s10147-018-1318-z. Epub 2018 Jul 19. Int J Clin Oncol. 2018. PMID: 30027464 Free article. Clinical Trial.
A randomized phase II trial of cisplatin plus gemcitabine versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT0703).
Fukumoto SI, Oizumi S, Harada M, Sukoh N, Nakano K, Fuke S, Sakakibara-Konishi J, Takamura K, Ito K, Fujita Y, Nishigaki Y, Harada T, Akie K, Kinoshita I, Amano T, Isobe H, Dosaka-Akita H, Nishimura M; Hokkaido Lung Cancer Clinical Study Group. Fukumoto SI, et al. Among authors: amano t. Cancer Chemother Pharmacol. 2020 Jul;86(1):117-127. doi: 10.1007/s00280-020-04104-1. Epub 2020 Jun 20. Cancer Chemother Pharmacol. 2020. PMID: 32564128 Clinical Trial.
Prognostic significance of OX40+ lymphocytes in tumor stroma of surgically resected small-cell lung cancer.
Yokouchi H, Nishihara H, Harada T, Amano T, Ohkuri T, Yamazaki S, Kikuchi H, Oizumi S, Uramoto H, Tanaka F, Harada M, Akie K, Sugaya F, Fujita Y, Takamura K, Kojima T, Higuchi M, Honjo O, Minami Y, Watanabe N, Nishimura M, Suzuki H, Dosaka-Akita H, Isobe H. Yokouchi H, et al. Among authors: amano t. Oncoimmunology. 2021 Sep 18;10(1):1971430. doi: 10.1080/2162402X.2021.1971430. eCollection 2021. Oncoimmunology. 2021. PMID: 34552823 Free PMC article.
Rikkunshito for Preventing Chemotherapy-Induced Nausea and Vomiting in Lung Cancer Patients: Results from 2 Prospective, Randomized Phase 2 Trials.
Harada T, Amano T, Ikari T, Takamura K, Ogi T, Fujikane T, Fujita Y, Taima K, Tanaka H, Sasaki T, Okumura S, Sugawara S, Yokouchi H, Yamada N, Morikawa N, Dosaka-Akita H, Isobe H, Nishimura M. Harada T, et al. Among authors: amano t. Front Pharmacol. 2018 Jan 16;8:972. doi: 10.3389/fphar.2017.00972. eCollection 2017. Front Pharmacol. 2018. PMID: 29387008 Free PMC article.
Phase II trial of combination treatment with S-1/cetuximab in patients with platinum-ineligible recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Taguchi J, Shimizu Y, Ariga S, Goda T, Ohhara Y, Honma R, Noguchi T, Takeuchi S, Kinoshita I, Amano T, Mizumachi T, Kano S, Takahara M, Abe T, Homma A, Dosaka-Akita H. Taguchi J, et al. Among authors: amano t. Int J Clin Oncol. 2021 Jan;26(1):51-58. doi: 10.1007/s10147-020-01788-6. Epub 2020 Sep 29. Int J Clin Oncol. 2021. PMID: 32996023 Clinical Trial.
Clinical significance of comprehensive genomic profiling tests covered by public insurance in patients with advanced solid cancers in Hokkaido, Japan.
Kikuchi J, Ohhara Y, Takada K, Tanabe H, Hatanaka K, Amano T, C Hatanaka K, Hatanaka Y, Mitamura T, Kato M, Shibata Y, Yabe I, Endoh A, Komatsu Y, Matsuno Y, Sugiyama M, Manabe A, Sakurai A, Takahashi M, Naruse H, Torimoto Y, Dosaka-Akita H, Kinoshita I. Kikuchi J, et al. Among authors: amano t. Jpn J Clin Oncol. 2021 Apr 30;51(5):753-761. doi: 10.1093/jjco/hyaa277. Jpn J Clin Oncol. 2021. PMID: 33532831
1,732 results